Abstract 16966: Effect of Adding Ezetimibe to Statins versus Statin Monotherapy in Cardiovascular Risk Reduction in Patients With Coronary Artery Disease - A Meta-analysis
Introduction: Statin therapy has been proven to reduce LDL levels and the risk of cardiovascular events. We sought to evaluate the incremental role of Ezetimibe in addition to on-going Statin therapy to assess changes in lipid profile and cardiovascular events.
Methods: A comprehensive search in Medline Indexed and Non-indexed was performed to search for randomized controlled trials that examined the role of Ezetimibe plus Statins compared to Statin monotherapy on lipid profile and cardiovascular event rate in patients with coronary artery disease (CAD). We used the mean change for continuous variables and event rates for dichotomous variables for calculating p- values.
Results: We included a total of 17 Randomized Control Trials (RCTs) with 22,603 patients, in our meta-analysis. Among these, 15 studies assessed biochemical improvement, whereas 2 RCTs with 18,186 patients evaluated the clinical outcomes. Summary effects were estimated using random effects model. The cumulative estimate showed that addition of Ezetimibe to Statins resulted in an overall mean reduction of total cholesterol (mean change -14.69 mg/dL, 95% CI -18.03, -10.34, p <0.00001), LDL (mean change -12.92 mg/dL, 95% CI -15.5, -12.34, p <0.00001), and triglycerides (mean change -9.94 mg/dL, 95% CI -13.33, -6.55, p <0.00001). However, there was no significant improvement in HDL level. There was also an 11% reduction in mortality with Ezetimibe addition (Odds Ratio 0.89, 95% CI 0.82, 0.96, p =0.002).
ConclusioN: In conclusion, addition of Ezetimibe to a Statin in patients with CAD results in a significant reduction in total cholesterol, LDL and triglycerides and also demonstrates a significant mortality benefit.
Author Disclosures: D. Banerji: None. Y. Akram: None. S. Somalaraju: None. R. Bajaj: None. L. Pacifico: None.
- © 2015 by American Heart Association, Inc.